CAR-T efficacy: is conditioning the key?

In this issue of Blood, Hirayama and colleagues report that a favorable cytokine profile induced by lymphodepletion is associated with durable remissions in patients with aggressive non-Hodgkin lymphoma treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.(1)